Skip to search formSkip to main contentSkip to account menu

balicatib

Known as: N-(1-((Cyanomethyl)carbamoyl)cyclohexyl)-4-(4-propylpiperazin-1-yl)benzamide 
National Institutes of Health

Related topics

Related topics

3 relations

Narrower (1)

AAE581

Broader (2)

BenzamidesPiperazines

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Study Progress in the Application of Bone Targeting Drugs for the Treatment of Osteoporosis
Belongs to the metabolic disease with the highest incidence rate. The middle-aged and elderly people are the main disease group… 
2017
2017
Identification of mouse cathepsin K structural elements that regulate the potency of odanacatib.
Cathepsin K (CatK) is the predominant mammalian bone-degrading protease and thus an ideal target for antiosteoporotic drug… 
2009
2009
Pharmacological inhibitors to identify roles of cathepsin K in cell-based studies: a comparison of available tools
Abstract Cathepsin K (Cat K) degrades bone type I collagen and is a target for the pharmacological treatment of osteoporosis… 
2006
2006
Population pharmacokinetics of balicatib, a cathepsin K inhibitor
Background: Cathepsin K is a key enzyme for the breakdown of collagen during bone resorption. Balicatib inhibits cathepsin K and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)